AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Chronic kidney disease and risks of adverse clinical events in patients with atrial fibrillation

Si-Tong LI1Chao JIANG1Liu HE1Qi-Fan LI1Zuohan DING2Jia-Hui WU1Rong HU1Qiang LV1Xu LI1Chang-Qi JIA1Yan-Fei RUAN1Man NING1Li FENG1Rong BAI1Ri-Bo TANG1Xin DU1,3( )Jian-Zeng DONG1Chang-Sheng MA1( )
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases, Beijing, China
University of Edinburgh, Edinburgh, UK
Heart Health Research Centre, Beijing, China
Show Author Information

Abstract

BACKGROUND

Chronic kidney disease (CKD) is highly prevalent in patients with atrial fibrillation (AF). However, the association between CKD and clinical consequences in AF patients is still under debate.

METHODS

We included 19,079 nonvalvular AF patients with available estimated glomerular filtration rate (eGFR) values in the Chinese Atrial Fibrillation Registry from 2011 to 2018. Patients were classified into no CKD (eGFR ≥ 90 mL/min per 1.73 m2), mild CKD (60 ≤ eGFR < 90 mL/min per 1.73 m2), moderate CKD (30 ≤ eGFR < 60 mL/min per 1.73 m2), and severe CKD (eGFR < 30 mL/min per 1.73 m2) groups. The risks of thromboembolism, major bleeding, and cardiovascular mortality were estimated with Fine-Gray regression analysis according to CKD status. Cox regression was performed to assess the risk of all-cause mortality associated with CKD.

RESULTS

Over a mean follow-up of 4.1 ± 1.9 years, there were 985 thromboembolic events, 414 major bleeding events, 956 cardiovascular deaths, and 1,786 all-cause deaths. After multivariate adjustment, CKD was not an independent risk factor of thromboembolic events. As compared to patients with no CKD, those with mild CKD, moderate CKD, and severe CKD had a 45%, 47%, and 133% higher risk of major bleeding, respectively. There was a graded increased risk of cardiovascular mortality associated with CKD status compared with no CKD group: adjusted hazard ratio [HR] was 1.34 (95% CI: 1.07−1.68, P = 0.011) for mild CKD group, 2.17 (95% CI: 1.67−2.81, P < 0.0001) for moderate CKD group, and 2.95 (95% CI: 1.97−4.41, P < 0.0001) for severe CKD group, respectively. Risk of all-cause mortality also increased among patients with moderate or severe CKD.

CONCLUSIONS

CKD status was independently associated with progressively higher risks of major bleeding and mortality, but didn’t seem to be an independent predictor of thromboembolism in AF patients.

Electronic Supplementary Material

Download File(s)
JGC-202103-034-ESM.pdf (1.2 MB)

References

[1]

Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102−1107.

[2]

Reinecke H, Nabauer M, Gerth A, et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney Int 2015; 87: 200−209.

[3]

Bonde AN, Lip GY, Kamper AL, et al. Renal Function and the Risk of Stroke and Bleeding in Patients With atrial fibrillation: an observational cohort study. Stroke 2016; 47: 2707−2713.

[4]

Goto S, Angchaisuksiri P, Bassand JP, et al. Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD-AF Registry. J Am Heart Assoc 2019; 8: e010510.

[5]

Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123: 2946−2953.

[6]

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42: 373−498.

[7]

Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA 2019; 322: 1294−1304.

[8]

Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019; 139: e56−e528.

[9]

Massera D, Wang D, Vorchheimer DA, et al. Increased risk of stroke and mortality following new-onset atrial fibrillation during hospitalization. Europace 2017; 19: 929−936.

[10]

Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625−635.

[11]

Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363−1369.

[12]

Lip GY, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014; 35: 3365−3376.

[13]

Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: 297−306.

[14]

Ding WY, Lip GYH, Pastori D, et al. Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events. Am J Cardiol 2020; 132: 72−78.

[15]

Boriani G, Laroche C, Diemberger I, et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep 2016; 6: 30271.

[16]

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140: e125−e151.

[17]

Hijazi Z, Oldgren J, Lindbäck J, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J 2018; 39: 477−485.

[18]

Du X, Ma C, Wu J, et al. Rationale and design of the Chinese Atrial Fibrillation Registry Study. BMC Cardiovasc Disord 2016; 16: 130.

[19]

Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825−830.

[20]

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604−612.

[21]

Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263−272.

[22]

Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093−1100.

[23]

Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692−694.

[24]

Abdel-Qadir H, Fang J, Lee DS, et al. Importance of considering competing risks in time-to-event analyses: application to stroke risk in a retrospective cohort study of elderly patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2018; 11: e004580.

[25]

Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013; 127: 224−232.

[26]

Banerjee A, Fauchier L, Vourc'h P, et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013; 61: 2079−2087.

[27]

O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36: 3258−3264.

[28]

Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395−401.

[29]

Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 2018; 14: 337−351.

[30]

Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol 2019; 74: 2204−2215.

[31]

Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, et al. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2016; 68: 2508−2521.

[32]

Yuzawa Y, Kuronuma K, Okumura Y, et al. Relationship between the renal function and adverse clinical events in patients with atrial fibrillation: a Japanese multicenter registry substudy. J Clin Med 2020: 9.

[33]

Arnson Y, Hoshen M, Berliner-Sendrey A, et al. Risk of stroke, bleeding, and death in patients with nonvalvular atrial fibrillation and chronic kidney disease. Cardiology 2020; 145: 178−186.

[34]

Banerjee A, Fauchier L, Vourc'h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014; 145: 1370−1382.

[35]

Wan H, Wang J, Yang Y, et al. Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation. BMC Cardiovasc Disord 2020; 20: 490.

[36]

Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers 2017; 3: 17088.

[37]

Freedman BI, Cohen AH. Hypertension-attributed nephropathy: what's in a name? Nat Rev Nephrol 2016; 12: 27−36.

[38]

Mihai S, Codrici E, Popescu ID, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res 2018; 2018: 2180373.

[39]

Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Semin Dial 2015; 28: 564−577.

[40]

Fauchier L, Bisson A, Clementy N, et al. Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. Am Heart J 2018; 198: 39−45.

[41]

Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J 2018; 39: 2314−2325.

[42]

Goel N, Jain D, Haddad DB, et al. Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences. J Stroke 2020; 22: 306−316.

[43]

Boriani G, Savelieva I, Dan GA, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015; 17: 1169−1196.

[44]

Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 2013; 168: 4678−4684.

Journal of Geriatric Cardiology
Pages 867-876
Cite this article:
LI S-T, JIANG C, HE L, et al. Chronic kidney disease and risks of adverse clinical events in patients with atrial fibrillation. Journal of Geriatric Cardiology, 2021, 18(11): 867-876. https://doi.org/10.11909/j.issn.1671-5411.2021.11.002

618

Views

22

Downloads

0

Crossref

3

Web of Science

3

Scopus

0

CSCD

Altmetrics

Published: 28 November 2021
© 2021 JGC All rights reserved
Return